Sixth biannual report of the cochrane haematological malignancies group - Focus on non-hodgkin lymphoma

Journal of the National Cancer Institute

Volumn 99, Issue 17, 2007, Pages

  Weingart, Olaf ^a   Rehan, Fareed A ^a   Schulz, Holger ^a   Naumann, Frauke ^a   Knauel, Ina ^a   Brillant, Corinne ^a   Bohlius, Julia ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD20 ANTIBODY; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLADDER CANCER; BONE MARROW TOXICITY; BREAST CANCER; CANCER STAGING; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INFECTION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG CANCER; LUNG TOXICITY; MANTLE CELL LYMPHOMA; MEDICAL RESEARCH; MONOTHERAPY; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; B CELL LYMPHOMA; BLOOD DISEASE; PROGNOSIS; STATISTICS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 34548649214     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm110     Document Type: Article

References (13)

1. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide,and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108(13):4003-4008.
2. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108(10):3295-3301.
3. Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2007; 99(9):706-714.
4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006; 7(5):379-391.
5. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19):3121-3127.
6. Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Science 2006; 97(4):305-312.
7. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international Lymphoma Study Group. Blood 1994; 84(5):1361-1392.
8. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23(4):250-257.
9. U.S. Department of Health and Human Services Food and Drug Administration - Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologies. Rockville MD: U.S Department of Health and Human Services Food and Drug Administration, 2007.
10. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108(8):2540-2544.
11. Rohatiner AZS, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma. J Clin Oncol 2005; 23(10):2215-2223.
12. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al, Follicular Lymphoma International Prognostic Index. Blood 2004; 104(5):1258-1265.
13. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJS, Kaiser U, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: Results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006; 17(10):1546-1552.